{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:49:44Z","timestamp":1793998184780,"version":"4.8.0"},"reference-count":156,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002803","name":"Fondazione Cariplo","doi-asserted-by":"publisher","award":["2018-0511"],"award-info":[{"award-number":["2018-0511"]}],"id":[{"id":"10.13039\/501100002803","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.phrs.2021.105812","type":"journal-article","created":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T06:14:33Z","timestamp":1629785673000},"page":"105812","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":74,"special_numbering":"C","title":["Lipoprotein(a): Knowns, unknowns and uncertainties"],"prefix":"10.1016","volume":"173","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0195-7061","authenticated-orcid":false,"given":"Massimiliano","family":"Ruscica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesare R.","family":"Sirtori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Corsini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald F.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.phrs.2021.105812_bib1","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.jacc.2021.01.051","article-title":"Emerging RNA therapeutics to lower blood levels of Lp(a): JACC focus seminar 2\/4","volume":"77","author":"Tsimikas","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"issue":"7","key":"10.1016\/j.phrs.2021.105812_bib2","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1194\/jlr.R051904","article-title":"Lipoprotein (a): impact by ethnicity and environmental and medical conditions","volume":"57","author":"Enkhmaa","year":"2016","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.phrs.2021.105812_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104916","article-title":"Clinical approach to the inflammatory etiology of cardiovascular diseases","volume":"159","author":"Ruscica","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"3","key":"10.1016\/j.phrs.2021.105812_bib4","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/MOL.0000000000000753","article-title":"The impact of race and ethnicity on lipoprotein(a) levels and cardiovascular risk","volume":"32","author":"Reyes-Soffer","year":"2021","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.phrs.2021.105812_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105689","article-title":"Beyond Lipoprotein(a) plasma measurements: lipoprotein(a) and inflammation","volume":"169","author":"Reyes-Soffer","year":"2021","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.phrs.2021.105812_bib6","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1161\/ATVBAHA.120.314965","article-title":"Genome-wide association study highlights APOH as a novel locus for lipoprotein(a) levels-brief report","volume":"41","author":"Hoekstra","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"8","key":"10.1016\/j.phrs.2021.105812_bib7","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1194\/jlr.R067314","article-title":"Structure, function, and genetics of lipoprotein (a)","volume":"57","author":"Schmidt","year":"2016","journal-title":"J. Lipid Res."},{"issue":"4","key":"10.1016\/j.phrs.2021.105812_bib8","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1194\/jlr.R061648","article-title":"Lipoprotein (a) measurements for clinical application","volume":"57","author":"Marcovina","year":"2016","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.phrs.2021.105812_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2020.03.003","article-title":"The dedicated \u201cLp(a) clinic\u201d: a concept whose time has arrived?","volume":"300","author":"Tsimikas","year":"2020","journal-title":"Atherosclerosis"},{"issue":"6","key":"10.1016\/j.phrs.2021.105812_bib10","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/MOL.0000000000000713","article-title":"The interconnection between lipoprotein(a), lipoprotein(a) cholesterol and true LDL-cholesterol in the diagnosis of familial hypercholesterolemia","volume":"31","author":"Yeang","year":"2020","journal-title":"Curr. Opin. Lipidol."},{"issue":"6","key":"10.1016\/j.phrs.2021.105812_bib11","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/MOL.0000000000000714","article-title":"Advances, gaps and opportunities in the detection of familial hypercholesterolemia: overview of current and future screening and detection methods","volume":"31","author":"Ibrahim","year":"2020","journal-title":"Curr. Opin. Lipidol."},{"key":"10.1016\/j.phrs.2021.105812_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104413","article-title":"A new dawn for managing dyslipidemias: the era of rna-based therapies","volume":"150","author":"Macchi","year":"2019","journal-title":"Pharmacol. Res."},{"issue":"24","key":"10.1016\/j.phrs.2021.105812_bib13","doi-asserted-by":"crossref","first-page":"11643","DOI":"10.1073\/pnas.90.24.11643","article-title":"Cys4057 of apolipoprotein(a) is essential for lipoprotein(a) assembly","volume":"90","author":"Brunner","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"26","key":"10.1016\/j.phrs.2021.105812_bib14","doi-asserted-by":"crossref","first-page":"19819","DOI":"10.1016\/S0021-9258(19)36587-1","article-title":"Identification of the cysteine residue in apolipoprotein(a) that mediates extracellular coupling with apolipoprotein B-100","volume":"268","author":"Koschinsky","year":"1993","journal-title":"J. Biol. Chem."},{"issue":"41","key":"10.1016\/j.phrs.2021.105812_bib15","doi-asserted-by":"crossref","first-page":"23914","DOI":"10.1074\/jbc.270.41.23914","article-title":"Site-specific mutagenesis demonstrates that cysteine 4326 of apolipoprotein B is required for covalent linkage with apolipoprotein (a) in vivo","volume":"270","author":"Callow","year":"1995","journal-title":"J. Biol. Chem."},{"issue":"6144","key":"10.1016\/j.phrs.2021.105812_bib16","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/330132a0","article-title":"cDNA sequence of human apolipoprotein(a) is homologous to plasminogen","volume":"330","author":"McLean","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2021.105812_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104858","article-title":"Apolipoprotein(a), an enigmatic anti-angiogenic glycoprotein in human plasma: a curse or cure?","volume":"158","author":"Kalaivani","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"4","key":"10.1016\/j.phrs.2021.105812_bib18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/hmg\/2.4.361","article-title":"The apolipoprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably-sized isoforms","volume":"2","author":"van der Hoek","year":"1993","journal-title":"Hum. Mol. Genet."},{"issue":"12","key":"10.1016\/j.phrs.2021.105812_bib19","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1016\/S0022-2275(20)37461-7","article-title":"Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans","volume":"37","author":"Marcovina","year":"1996","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/j.phrs.2021.105812_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1194\/jlr.R071571","article-title":"Lipoprotein (a): a historical appraisal","volume":"58","author":"Kostner","year":"2017","journal-title":"J. Lipid Res."},{"issue":"26","key":"10.1016\/j.phrs.2021.105812_bib21","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.phrs.2021.105812_bib22","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1093\/eurheartj\/ehx174","article-title":"A novel but frequent variant in LPA KIV-2 is associated with a pronounced Lp(a) and cardiovascular risk reduction","volume":"38","author":"Coassin","year":"2017","journal-title":"Eur. Heart J."},{"issue":"5","key":"10.1016\/j.phrs.2021.105812_bib23","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jacc.2021.05.037","article-title":"Frequent LPA KIV-2 variants lower lipoprotein(a) concentrations and protect against coronary artery disease","volume":"78","author":"Schachtl-Riess","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.phrs.2021.105812_bib24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13073-020-00771-0","article-title":"Investigation of a nonsense mutation located in the complex KIV-2 copy number variation region of apolipoprotein(a) in 10,910 individuals","volume":"12","author":"Di Maio","year":"2020","journal-title":"Genome Med."},{"issue":"3","key":"10.1016\/j.phrs.2021.105812_bib25","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1161\/ATVBAHA.116.308704","article-title":"Lipoprotein(a) mass levels increase significantly according to APOE genotype: an analysis of 431 239 patients","volume":"37","author":"Moriarty","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"9","key":"10.1016\/j.phrs.2021.105812_bib26","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1194\/jlr.R077693","article-title":"The metabolism of lipoprotein (a): an ever-evolving story","volume":"58","author":"Reyes-Soffer","year":"2017","journal-title":"J. Lipid Res."},{"issue":"7","key":"10.1016\/j.phrs.2021.105812_bib27","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.011781","article-title":"Lipoprotein(a) particle production as a determinant of plasma lipoprotein(a) concentration across varying apolipoprotein(a) isoform sizes and background cholesterol-lowering therapy","volume":"8","author":"Chan","year":"2019","journal-title":"J. Am. Heart Assoc."},{"issue":"6","key":"10.1016\/j.phrs.2021.105812_bib28","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jacbts.2020.03.008","article-title":"Lipoprotein(a) cellular uptake ex vivo and hepatic capture in vivo is insensitive to PCSK9 inhibition with alirocumab","volume":"5","author":"Chemello","year":"2020","journal-title":"JACC Basic Transl. Sci."},{"issue":"2","key":"10.1016\/j.phrs.2021.105812_bib29","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pathol.2018.11.003","article-title":"Lipoprotein(a) catabolism: a case of multiple receptors","volume":"51","author":"McCormick","year":"2019","journal-title":"Pathology"},{"issue":"Pt. 3","key":"10.1016\/j.phrs.2021.105812_bib30","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1042\/bj20030932","article-title":"Galactose-specific asialoglycoprotein receptor is involved in lipoprotein (a) catabolism","volume":"376","author":"Hrzenjak","year":"2003","journal-title":"Biochem. J."},{"issue":"2","key":"10.1016\/j.phrs.2021.105812_bib31","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jacc.2017.11.014","article-title":"NHLBI working group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis","volume":"71","author":"Tsimikas","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2021.105812_bib32","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.atherosclerosis.2019.08.015","article-title":"Comparison of lipoprotein (a) serum concentrations measured by six commercially available immunoassays","volume":"289","author":"Scharnagl","year":"2019","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.phrs.2021.105812_bib33","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/HCO.0000000000000842","article-title":"Contemporary perspectives on the genetics and clinical use of lipoprotein(a) in preventive cardiology","volume":"36","author":"Page","year":"2021","journal-title":"Curr. Opin. Cardiol."},{"issue":"2","key":"10.1016\/j.phrs.2021.105812_bib34","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0022-2275(20)30165-6","article-title":"Apolipoprotein [a] genotype influences isoform dominance pattern differently in African Americans and Caucasians","volume":"43","author":"Rubin","year":"2002","journal-title":"J. Lipid Res."},{"issue":"2","key":"10.1016\/j.phrs.2021.105812_bib35","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/clinchem\/41.2.246","article-title":"Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a)","volume":"41","author":"Marcovina","year":"1995","journal-title":"Clin. Chem."},{"key":"10.1016\/j.phrs.2021.105812_bib36","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/clinchem\/hvaa324","article-title":"Development of an LC-MS\/MS proposed candidate reference method for the standardization of analytical methods to measure lipoprotein(a)","volume":"67","author":"Marcovina","year":"2021","journal-title":"Clin. Chem."},{"issue":"12","key":"10.1016\/j.phrs.2021.105812_bib37","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1093\/clinchem\/46.12.1956","article-title":"Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a)","volume":"46","author":"Marcovina","year":"2000","journal-title":"Clin. Chem."},{"issue":"5","key":"10.1016\/j.phrs.2021.105812_bib38","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.jacl.2018.07.003","article-title":"Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size","volume":"12","author":"Tsimikas","year":"2018","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.phrs.2021.105812_bib39","first-page":"412","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Emerging Risk Factors","year":"2009"},{"issue":"22","key":"10.1016\/j.phrs.2021.105812_bib40","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.phrs.2021.105812_bib41","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S2213-8587(17)30088-8","article-title":"Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis","volume":"5","author":"Saleheen","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"2","key":"10.1016\/j.phrs.2021.105812_bib42","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1161\/CIRCULATIONAHA.107.715698","article-title":"Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study","volume":"117","author":"Kamstrup","year":"2008","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.phrs.2021.105812_bib43","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1194\/jlr.R071233","article-title":"Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology","volume":"57","author":"Nordestgaard","year":"2016","journal-title":"J. Lipid Res."},{"issue":"6","key":"10.1016\/j.phrs.2021.105812_bib44","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1001\/archinte.168.6.598","article-title":"Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data","volume":"168","author":"Bennet","year":"2008","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.phrs.2021.105812_bib45","article-title":"Plasma lipoprotein(a) measured in the routine clinical care is associated to atherosclerotic cardiovascular disease during a 14-year follow-up","author":"Littmann","year":"2021","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"1","key":"10.1016\/j.phrs.2021.105812_bib46","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (Lipoprotein[a]) concentrations and incident atherosclerotic cardiovascular disease: new insights from a large national biobank","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"5","key":"10.1016\/j.phrs.2021.105812_bib47","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.phrs.2021.105812_bib48","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1194\/jlr.P066258","article-title":"Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study","volume":"57","author":"Verbeek","year":"2016","journal-title":"J. Lipid Res."},{"issue":"12","key":"10.1016\/j.phrs.2021.105812_bib49","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1161\/ATVBAHA.113.302479","article-title":"Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease","volume":"33","author":"Nestel","year":"2013","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.phrs.2021.105812_bib50","article-title":"Lipoprotein(a) and cardiovascular disease: prediction, attributable risk fraction, and estimating benefits from novel interventions","author":"Welsh","year":"2020","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"1","key":"10.1016\/j.phrs.2021.105812_bib51","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1161\/ATVBAHA.119.312951","article-title":"Lipoprotein(a)-lowering by 50\u2009mg\/dL (105\u2009nmol\/L) may be needed to reduce cardiovascular disease 20% in secondary prevention: a population-based study","volume":"40","author":"Madsen","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"7","key":"10.1016\/j.phrs.2021.105812_bib52","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a mendelian randomization analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol."},{"issue":"6","key":"10.1016\/j.phrs.2021.105812_bib53","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/jamacardio.2019.1041","article-title":"Estimation of the required lipoprotein(a)-lowering therapeutic effect size for reduction in coronary heart disease outcomes: a mendelian randomization analysis","volume":"4","author":"Lamina","year":"2019","journal-title":"JAMA Cardiol."},{"issue":"12","key":"10.1016\/j.phrs.2021.105812_bib54","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1093\/eurheartj\/ehaa1085","article-title":"Low lipoprotein(a) levels and risk of disease in a large, contemporary, general population study","volume":"42","author":"Langsted","year":"2021","journal-title":"Eur. Heart J."},{"issue":"7","key":"10.1016\/j.phrs.2021.105812_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004494","article-title":"Distribution and medical impact of loss-of-function variants in the Finnish founder population","volume":"10","author":"Lim","year":"2014","journal-title":"PLoS Genet."},{"issue":"9","key":"10.1016\/j.phrs.2021.105812_bib56","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1161\/ATVBAHA.114.303462","article-title":"A common LPA null allele associates with lower lipoprotein(a) levels and coronary artery disease risk","volume":"34","author":"Kyriakou","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"24","key":"10.1016\/j.phrs.2021.105812_bib57","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2019.10.019","article-title":"Lipoprotein(a) concentration and risks of cardiovascular disease and diabetes","volume":"74","author":"Gudbjartsson","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"25","key":"10.1016\/j.phrs.2021.105812_bib58","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1016\/j.jacc.2016.10.033","article-title":"Phenotypic characterization of genetically lowered human lipoprotein(a) levels","volume":"68","author":"Emdin","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.phrs.2021.105812_bib59","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10557-016-6648-3","article-title":"Human genetics and the causal role of lipoprotein(a) for various diseases","volume":"30","author":"Kronenberg","year":"2016","journal-title":"Cardiovasc. Drugs Ther."},{"key":"10.1016\/j.phrs.2021.105812_bib60","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamacardio.2020.5398","article-title":"Clinical utility of lipoprotein(a) and LPA genetic risk score in risk prediction of incident atherosclerotic cardiovascular disease","volume":"6","author":"Trinder","year":"2021","journal-title":"JAMA Cardiol."},{"issue":"12","key":"10.1016\/j.phrs.2021.105812_bib61","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1161\/CIRCULATIONAHA.118.034311","article-title":"Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups","volume":"139","author":"Pare","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.phrs.2021.105812_bib62","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1038\/s41467-018-04668-w","article-title":"Deep coverage whole genome sequences and plasma lipoprotein(a) in individuals of European and African ancestries","volume":"9","author":"Zekavat","year":"2018","journal-title":"Nat. Commun."},{"issue":"17","key":"10.1016\/j.phrs.2021.105812_bib63","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1161\/CIRCULATIONAHA.117.031356","article-title":"LPA Variants are associated with residual cardiovascular risk in patients receiving statins","volume":"138","author":"Wei","year":"2018","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.phrs.2021.105812_bib64","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1161\/CIRCGENETICS.111.959601","article-title":"Genetic variants in the apolipoprotein(a) gene and coronary heart disease","volume":"4","author":"Li","year":"2011","journal-title":"Circ. Cardiovasc. Genet."},{"issue":"7","key":"10.1016\/j.phrs.2021.105812_bib65","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S2213-8587(17)30096-7","article-title":"Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study","volume":"5","author":"Zewinger","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"9","key":"10.1016\/j.phrs.2021.105812_bib66","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1194\/jlr.M076232","article-title":"A genome-wide association meta-analysis on lipoprotein (a) concentrations adjusted for apolipoprotein (a) isoforms","volume":"58","author":"Mack","year":"2017","journal-title":"J. Lipid Res."},{"issue":"5","key":"10.1016\/j.phrs.2021.105812_bib67","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jacc.2021.06.004","article-title":"Genetics to the rescue: sophisticated approaches provide critical insights into the determination of Lp(a) levels","volume":"78","author":"Koschinsky","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"issue":"Suppl. 1","key":"10.1016\/j.phrs.2021.105812_bib68","first-page":"S5","article-title":"Prediction of cardiovascular risk by Lp(a) concentrations or genetic variants within the LPA gene region","volume":"14","author":"Kronenberg","year":"2019","journal-title":"Clin. Res. Cardiol."},{"issue":"1","key":"10.1016\/j.phrs.2021.105812_bib69","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1194\/jlr.M090381","article-title":"A comprehensive map of single-base polymorphisms in the hypervariable LPA kringle IV type 2 copy number variation region","volume":"60","author":"Coassin","year":"2019","journal-title":"J. Lipid Res."},{"issue":"5","key":"10.1016\/j.phrs.2021.105812_bib70","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41569-018-0153-2","article-title":"Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease","volume":"16","author":"Boffa","year":"2019","journal-title":"Nat. Rev. Cardiol."},{"issue":"1","key":"10.1016\/j.phrs.2021.105812_bib71","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa043175","article-title":"Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease","volume":"353","author":"Tsimikas","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.phrs.2021.105812_bib72","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.atherosclerosis.2009.09.077","article-title":"The I4399M variant of apolipoprotein(a) is associated with increased oxidized phospholipids on apolipoprotein B-100 particles","volume":"209","author":"Arai","year":"2010","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.phrs.2021.105812_bib73","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1161\/CIRCULATIONAHA.111.045120","article-title":"Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study","volume":"125","author":"Virani","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2021.105812_bib74","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.120.003354","article-title":"Associations of genetically predicted Lp(a) (Lipoprotein [a]) levels with cardiovascular traits in individuals of European and African Ancestry","volume":"14","author":"Satterfield","year":"2021","journal-title":"Circ. Genom. Precis. Med."},{"issue":"3","key":"10.1016\/j.phrs.2021.105812_bib75","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/ng.768","article-title":"Discovery and genotyping of genome structural polymorphism by sequencing on a population scale","volume":"43","author":"Handsaker","year":"2011","journal-title":"Nat. Genet."},{"issue":"32","key":"10.1016\/j.phrs.2021.105812_bib76","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1093\/eurheartj\/ehx166","article-title":"Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium","volume":"38","author":"Waldeyer","year":"2017","journal-title":"Eur. Heart J."},{"issue":"5","key":"10.1016\/j.phrs.2021.105812_bib77","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1161\/ATVBAHA.118.310865","article-title":"Genetic factors explain a major fraction of the 50% lower lipoprotein(a) concentrations in finns","volume":"38","author":"Erhart","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"3","key":"10.1016\/j.phrs.2021.105812_bib78","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1161\/CIRCULATIONAHA.116.024611","article-title":"LPA Gene ethnicity, and cardiovascular events","volume":"135","author":"Lee","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2021.105812_bib79","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.120.003271","article-title":"Sex-specific associations of genetically predicted circulating Lp(a) (Lipoprotein(a)) and hepatic LPA gene expression levels with cardiovascular outcomes: mendelian randomization and observational analyses","volume":"14","author":"Guertin","year":"2021","journal-title":"Circ. Genom. Precis. Med."},{"issue":"2","key":"10.1016\/j.phrs.2021.105812_bib80","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1161\/01.ATV.17.2.239","article-title":"A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants","volume":"17","author":"Wild","year":"1997","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"2","key":"10.1016\/j.phrs.2021.105812_bib81","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0021-9150(00)00427-5","article-title":"Lipoprotein(a) associated with coronary artery disease in older women: age and gender analysis","volume":"153","author":"Foody","year":"2000","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2021.105812_bib82","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejim.2016.08.018","article-title":"Serum lipoprotein(a) level as long-term predictor of cardiovascular mortality in a large sample of subjects in primary cardiovascular prevention: data from the Brisighella Heart Study","volume":"37","author":"Fogacci","year":"2017","journal-title":"Eur. J. Intern. Med."},{"issue":"3","key":"10.1016\/j.phrs.2021.105812_bib83","article-title":"Gender difference in lipoprotein(a) concentration as a predictor of coronary revascularization in patients with known coronary artery disease","volume":"1866","author":"Bigazzi","year":"2021","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"issue":"6","key":"10.1016\/j.phrs.2021.105812_bib84","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1109034","article-title":"Genetic associations with valvular calcification and aortic stenosis","volume":"368","author":"Thanassoulis","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.phrs.2021.105812_bib85","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jacc.2019.03.524","article-title":"Elevated lipoprotein(a) and risk of ischemic stroke","volume":"74","author":"Langsted","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.phrs.2021.105812_bib86","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1161\/ATVBAHA.114.304785","article-title":"Race is a key variable in assigning lipoprotein(a) cutoff values for coronary heart disease risk assessment: the Multi-Ethnic Study of Atherosclerosis","volume":"35","author":"Guan","year":"2015","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"11","key":"10.1016\/j.phrs.2021.105812_bib87","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1161\/ATVBAHA.116.308011","article-title":"Prevalence of elevated Lp(a) mass levels and patient thresholds in 532 359 patients in the United States","volume":"36","author":"Varvel","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.phrs.2021.105812_bib88","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/joim.12981","article-title":"Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities","volume":"287","author":"Vuorio","year":"2020","journal-title":"J. Intern. Med."},{"issue":"19","key":"10.1016\/j.phrs.2021.105812_bib89","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1016\/j.jacc.2014.01.063","article-title":"Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation","volume":"63","author":"Alonso","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"22","key":"10.1016\/j.phrs.2021.105812_bib90","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1093\/eurheartj\/ehab218","article-title":"Suboptimal lipoprotein (a) control and residual plaque instability despite proprotein convertase subtilisin\/kexin type 9 inhibitor use in heterozygous familial hypercholesterolaemia: insights from serial near-infrared spectroscopy imaging","volume":"42","author":"Imamoto","year":"2021","journal-title":"Eur. Heart J."},{"issue":"22","key":"10.1016\/j.phrs.2021.105812_bib91","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1161\/CIRCULATIONAHA.116.024541","article-title":"Predicting cardiovascular events in familial hypercholesterolemia: the SAFEHEART registry (Spanish Familial Hypercholesterolemia Cohort Study)","volume":"135","author":"Perez de Isla","year":"2017","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.phrs.2021.105812_bib92","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jacc.2018.12.037","article-title":"Value of measuring lipoprotein(a) during cascade testing for familial hypercholesterolemia","volume":"73","author":"Ellis","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2021.105812_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2021.100062","article-title":"Lipoprotein metabolism in familial hypercholesterolemia","volume":"62","author":"Chemello","year":"2021","journal-title":"J. Lipid Res."},{"issue":"21","key":"10.1016\/j.phrs.2021.105812_bib94","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1016\/j.jacc.2020.03.065","article-title":"Ascertainment bias in the association between elevated lipoprotein(a) and familial hypercholesterolemia","volume":"75","author":"Trinder","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2021.105812_bib95","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.cca.2020.07.029","article-title":"Coronary artery disease and the risk-associated LPA variants, rs3798220 and rs10455872, in patients with suspected familial hypercholesterolaemia","volume":"510","author":"Page","year":"2020","journal-title":"Clin. Chim. Acta"},{"issue":"7","key":"10.1016\/j.phrs.2021.105812_bib96","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S2213-8587(16)30042-0","article-title":"High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: a prospective cohort study","volume":"4","author":"Langsted","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.phrs.2021.105812_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2021.100053","article-title":"Novel method for quantification of lipoprotein(a)-cholesterol: Implications for improving accuracy of LDL-C measurements","volume":"62","author":"Yeang","year":"2021","journal-title":"J. Lipid Res."},{"issue":"2","key":"10.1016\/j.phrs.2021.105812_bib98","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.atherosclerosis.2015.08.021","article-title":"Lipoprotein (a) as a risk factor for ischemic stroke: a meta-analysis","volume":"242","author":"Nave","year":"2015","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1016\/j.phrs.2021.105812_bib99","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1161\/STROKEAHA.119.026872","article-title":"Causal effect of Lp(a) [Lipoprotein(a)] level on ischemic stroke and alzheimer disease: a mendelian randomization study","volume":"50","author":"Pan","year":"2019","journal-title":"Stroke"},{"issue":"6","key":"10.1016\/j.phrs.2021.105812_bib100","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1161\/01.STR.0000222666.21482.b6","article-title":"Lipoprotein(a) and incident ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study","volume":"37","author":"Ohira","year":"2006","journal-title":"Stroke"},{"issue":"5","key":"10.1016\/j.phrs.2021.105812_bib101","doi-asserted-by":"crossref","first-page":"212","DOI":"10.21037\/atm.2020.01.38","article-title":"Association between lipoprotein(a) concentration and the risk of stroke in the Chinese Han population: a retrospective case-control study","volume":"8","author":"Fu","year":"2020","journal-title":"Ann. Transl. Med."},{"issue":"22","key":"10.1016\/j.phrs.2021.105812_bib102","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1093\/eurheartj\/ehab081","article-title":"Lipoprotein(a) is associated with large artery atherosclerosis stroke aetiology and stroke recurrence among patients below the age of 60 years: results from the BIOSIGNAL study","volume":"42","author":"Arnold","year":"2021","journal-title":"Eur. Heart J."},{"issue":"22","key":"10.1016\/j.phrs.2021.105812_bib103","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1161\/CIRCULATIONAHA.120.045826","article-title":"Lipoprotein(a) in alzheimer, atherosclerotic, cerebrovascular, thrombotic, and valvular disease: mendelian randomization investigation","volume":"141","author":"Larsson","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2021.105812_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104861","article-title":"Diabetes and calcification: the potential role of anti-diabetic drugs on vascular calcification regression","volume":"158","author":"Ghosh","year":"2020","journal-title":"Pharmacol. Res."},{"issue":"12","key":"10.1016\/j.phrs.2021.105812_bib105","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1001\/jamacardio.2018.3798","article-title":"Association of mild to moderate aortic valve stenosis progression with higher lipoprotein(a) and oxidized phospholipid levels: secondary analysis of a randomized clinical trial","volume":"3","author":"Capoulade","year":"2018","journal-title":"JAMA Cardiol."},{"issue":"17","key":"10.1016\/j.phrs.2021.105812_bib106","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jacc.2019.01.070","article-title":"Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis","volume":"73","author":"Zheng","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.phrs.2021.105812_bib107","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1161\/CIRCRESAHA.118.313864","article-title":"Potential causality and emerging medical therapies for lipoprotein(a) and its associated oxidized phospholipids in calcific aortic valve stenosis","volume":"124","author":"Tsimikas","year":"2019","journal-title":"Circ. Res."},{"issue":"8","key":"10.1016\/j.phrs.2021.105812_bib108","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1161\/ATVBAHA.116.308761","article-title":"Oxidized phospholipids and risk of calcific aortic valve disease: the copenhagen general population study","volume":"37","author":"Kamstrup","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"17","key":"10.1016\/j.phrs.2021.105812_bib109","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1136\/heartjnl-2021-319044","article-title":"Lipoprotein(a) is robustly associated with aortic valve calcium","volume":"107","author":"Kaiser","year":"2021","journal-title":"Heart"},{"issue":"7","key":"10.1016\/j.phrs.2021.105812_bib110","doi-asserted-by":"crossref","DOI":"10.3390\/metabo11070459","article-title":"Lipoprotein proteomics and aortic valve transcriptomics identify biological pathways linking lipoprotein(a) levels to aortic stenosis","volume":"11","author":"Bourgeois","year":"2021","journal-title":"Metabolites"},{"issue":"8","key":"10.1016\/j.phrs.2021.105812_bib111","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1161\/01.ATV.18.8.1335","article-title":"Insulin and 2-hour glucose levels are inversely related to Lp(a) concentrations controlled for LPA genotype","volume":"18","author":"Rainwater","year":"1998","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"2","key":"10.1016\/j.phrs.2021.105812_bib112","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/MED.0000000000000597","article-title":"Lipoprotein (a) and diabetes mellitus: causes and consequences","volume":"28","author":"Ward","year":"2021","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"issue":"1","key":"10.1016\/j.phrs.2021.105812_bib113","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12933-017-0520-z","article-title":"Lipoprotein(a) and incident type-2 diabetes: results from the prospective Bruneck study and a meta-analysis of published literature","volume":"16","author":"Paige","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"issue":"3","key":"10.1016\/j.phrs.2021.105812_bib114","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S2213-8587(13)70064-0","article-title":"Lipoprotein(a) concentrations, isoform size, and risk of type 2 diabetes: a Mendelian randomisation study","volume":"1","author":"Kamstrup","year":"2013","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"2","key":"10.1016\/j.phrs.2021.105812_bib115","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s005920300007","article-title":"The relationship between lipoprotein(a) and the complications of diabetes mellitus","volume":"40","author":"Koschinsky","year":"2003","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.phrs.2021.105812_bib116","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.atherosclerosis.2019.07.003","article-title":"Therapeutic lowering of lipoprotein(a): how much is enough?","volume":"288","author":"Kronenberg","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2021.105812_bib117","article-title":"The scientific basis and future of lipoprotein apheresis","author":"Thompson","year":"2021","journal-title":"Ther. Apher. Dial."},{"issue":"10","key":"10.1016\/j.phrs.2021.105812_bib118","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/FPC.0b013e3283642fd6","volume":"23","author":"Donnelly","year":"2013","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.phrs.2021.105812_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105275","article-title":"Effect of different types and dosages of statins on plasma lipoprotein(a) levels: A network meta-analysis","volume":"163","author":"Wang","year":"2021","journal-title":"Pharmacol. Res."},{"issue":"2","key":"10.1016\/j.phrs.2021.105812_bib120","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGEN.117.001696","article-title":"Impact of apolipoprotein(a) isoform size on lipoprotein(a) lowering in the HPS2-THRIVE study","volume":"11","author":"Parish","year":"2018","journal-title":"Circ. Genom. Precis. Med."},{"issue":"11","key":"10.1016\/j.phrs.2021.105812_bib121","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.metabol.2016.08.007","article-title":"Effect of extended-release niacin on plasma lipoprotein(a) levels: a systematic review and meta-analysis of randomized placebo-controlled trials","volume":"65","author":"Sahebkar","year":"2016","journal-title":"Metabolism"},{"issue":"11","key":"10.1016\/j.phrs.2021.105812_bib122","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1194\/jlr.M029769","article-title":"Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice","volume":"53","author":"Chennamsetty","year":"2012","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.phrs.2021.105812_bib123","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.phrs.2017.12.028","article-title":"Present therapeutic role of cholesteryl ester transfer protein inhibitors","volume":"128","author":"Ferri","year":"2018","journal-title":"Pharmacol. Res."},{"issue":"9","key":"10.1016\/j.phrs.2021.105812_bib124","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1161\/ATVBAHA.117.309549","article-title":"CETP (Cholesteryl Ester Transfer Protein) inhibition with anacetrapib decreases production of lipoprotein(a) in mildly hypercholesterolemic subjects","volume":"37","author":"Thomas","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"7","key":"10.1016\/j.phrs.2021.105812_bib125","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s40265-019-01114-z","article-title":"Efficacy and safety of mipomersen: a systematic review and meta-analysis of randomized clinical trials","volume":"79","author":"Fogacci","year":"2019","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.phrs.2021.105812_bib126","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s40265-019-01243-5","article-title":"Potential of lipoprotein(a)-lowering strategies in treating coronary artery disease","volume":"80","author":"Gencer","year":"2020","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.phrs.2021.105812_bib127","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1210\/clinem\/dgaa672","article-title":"Treatment of Thyroid Dysfunction and Serum Lipids: A Systematic Review and Meta-analysis.","volume":"105","author":"Kotwal","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.phrs.2021.105812_bib128","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.bbadis.2010.12.019","article-title":"Role of thyroid receptor beta in lipid metabolism","volume":"1812","author":"Pramfalk","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"issue":"15","key":"10.1016\/j.phrs.2021.105812_bib129","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s40265-017-0791-4","article-title":"Potential role of thyroid receptor beta agonists in the treatment of hyperlipidemia","volume":"77","author":"Jakobsson","year":"2017","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.phrs.2021.105812_bib130","first-page":"121","article-title":"Lipoprotein(a) and apolipoprotein B plasma concentrations in hypothyroid, euthyroid, and hyperthyroid subjects","volume":"76","author":"de Bruin","year":"1993","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2021.105812_bib131","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.atherosclerosis.2019.07.015","article-title":"PCSK9 inhibition and inflammation: a narrative review","volume":"288","author":"Ruscica","year":"2019","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.phrs.2021.105812_bib132","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/FJC.0000000000000963","article-title":"Lipoprotein(a) reduction with proprotein convertase subtilisin\/kexin type 9 inhibitors: a systematic review and meta-analysis","volume":"77","author":"Farmakis","year":"2021","journal-title":"J. Cardiovasc. Pharmacol."},{"issue":"44","key":"10.1016\/j.phrs.2021.105812_bib133","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1093\/eurheartj\/ehaa649","article-title":"Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial","volume":"41","author":"Szarek","year":"2020","journal-title":"Eur. Heart J."},{"issue":"5","key":"10.1016\/j.phrs.2021.105812_bib134","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jacc.2021.04.102","article-title":"Lipoprotein(a) and benefit of PCSK9 inhibition in patients with nominally controlled LDL cholesterol","volume":"78","author":"Schwartz","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"issue":"12","key":"10.1016\/j.phrs.2021.105812_bib135","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk","volume":"139","author":"O\u2019Donoghue","year":"2019","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.phrs.2021.105812_bib136","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12933-021-01287-6","article-title":"Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: an analysis from BANTING and BERSON","volume":"20","author":"Lorenzatti","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"issue":"1","key":"10.1016\/j.phrs.2021.105812_bib137","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12933-020-0991-1","article-title":"Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol","volume":"19","author":"Colhoun","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.phrs.2021.105812_bib138","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehz746.0015","article-title":"Inclisiran-mediated reductions in Lp(a) in the ORION-1 trial","volume":"40","author":"Stoekenbroek","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2021.105812_bib139","article-title":"The size of apolipoprotein (a) is an independent determinant of the reduction in lipoprotein (a) induced by PCSK9 inhibitors","author":"Blanchard","year":"2021","journal-title":"Cardiovasc. Res."},{"issue":"27","key":"10.1016\/j.phrs.2021.105812_bib140","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1093\/eurheartj\/ehy122","article-title":"Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics","volume":"39","author":"Watts","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2021.105812_bib141","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154221","article-title":"PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a)","volume":"107","author":"Watts","year":"2020","journal-title":"Metabolism"},{"issue":"3","key":"10.1016\/j.phrs.2021.105812_bib142","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2021.105812_bib143","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.atherosclerosis.2021.03.036","article-title":"Prevalence and influence of LPA gene variants and isoform size on the Lp(a)-lowering effect of pelacarsen","volume":"324","author":"Karwatowska-Prokopczuk","year":"2021","journal-title":"Atherosclerosis"},{"issue":"7","key":"10.1016\/j.phrs.2021.105812_bib144","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.3390\/jcm9072103","article-title":"Lipoprotein(a) lowering-from lipoprotein apheresis to antisense oligonucleotide approach","volume":"9","author":"Greco","year":"2020","journal-title":"J. Clin. Med."},{"issue":"20","key":"10.1016\/j.phrs.2021.105812_bib145","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1093\/eurheartj\/ehx178","article-title":"Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial","volume":"38","author":"Khan","year":"2017","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.phrs.2021.105812_bib146","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.phrs.2021.105812_bib147","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1177\/0004563220968473","article-title":"Lp(a): when and how to measure it","volume":"58","author":"Cegla","year":"2021","journal-title":"Ann. Clin. Biochem."},{"key":"10.1016\/j.phrs.2021.105812_bib148","first-page":"e1046","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.phrs.2021.105812_bib149","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.cjca.2021.03.016","article-title":"2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.phrs.2021.105812_bib150","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.atherosclerosis.2019.10.011","article-title":"HEART UK consensus statement on Lipoprotein(a): a call to action","volume":"291","author":"Cegla","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2021.105812_bib151","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jpeds.2020.08.042","article-title":"Should Lipoprotein(a) be measured in youth?","volume":"228","author":"Kohn","year":"2021","journal-title":"J. Pediatr."},{"issue":"3","key":"10.1016\/j.phrs.2021.105812_bib152","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jacl.2019.04.010","article-title":"Use of Lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association","volume":"13","author":"Wilson","year":"2019","journal-title":"J. Clin. Lipidol."},{"issue":"2","key":"10.1016\/j.phrs.2021.105812_bib153","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/MED.0000000000000609","article-title":"Novel behavioural approaches and implementation science for mitigating genetic risk of cardiovascular disease due to elevated lipoprotein(a)","volume":"28","author":"Mullan","year":"2021","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"issue":"10","key":"10.1016\/j.phrs.2021.105812_bib154","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.jacc.2019.03.009","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"74","author":"Arnett","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.phrs.2021.105812_bib155","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.pcad.2016.07.005","article-title":"The re-emergence of lipoprotein(a) in a broader clinical arena","volume":"59","author":"Tsimikas","year":"2016","journal-title":"Prog. Cardiovasc. Dis."},{"issue":"8","key":"10.1016\/j.phrs.2021.105812_bib156","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11883-021-00937-0","article-title":"Genetics of lipoprotein(a): cardiovascular disease and future therapy","volume":"23","author":"Langsted","year":"2021","journal-title":"Curr. Atheroscler. Rep."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821003960?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661821003960?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T01:47:55Z","timestamp":1734400075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661821003960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":156,"alternative-id":["S1043661821003960"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105812","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipoprotein(a): Knowns, unknowns and uncertainties","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2021.105812","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105812"}}